Intismeran Autogene Therapy: An End-to-End Pathway From Tumor Tissue to Individualized Neoantigen Treatment for Patients With Cancer
JCO Oncology Advances · 2026-07 · 3 (3)
DOI: 10.1200/oa-25-00206 ↗Abstract
Intismeran autogene (V940/mRNA-4157; hereafter referred to as intismeran) is an individualized mRNA-based cancer immunotherapy targeting tumor-specific neoantigens. As a first-in-class therapy, intismeran is under clinical investigation across a range of settings, from early-stage disease (neoadjuvant and adjuvant) to advanced metastatic cancers—a broad clinical development program bolstered by positive phase II data in high-risk, resected melanoma. This article describes the process by which intismeran doses are generated and delivered to clinical sites, with an emphasis on individualized operational and manufacturing processes. Experience in intismeran early-phase trials provides confidence in the transition to broader, real-world oncologic applications.
EUVIMED